Eskil Elmr - Abliva AB Chief Discovery

ABLI Stock

SEK 0.43 0.01 2.38%

Insider

Eskil Elmr is Chief Discovery of Abliva AB

Age	53
Phone	46 4 62 75 62 20
Web	https://abliva.com

Abliva AB Management Efficiency

The company has return on total asset (ROA) of (0.4101) % which means that it has lost $0.4101 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.805) %, meaning that it generated substantial loss on money invested by shareholders. Abliva AB's management efficiency ratios could be used to measure how well Abliva AB manages its routine affairs as well as how well it operates its assets and liabilities.

Compare Abliva AB to Peers

Predict price of Abliva AB

Abliva AB has accumulated 92 K in total debt. Abliva AB has a current ratio of 2.7, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Abliva AB until it has trouble settling it off, either with new capital or with free cash flow. So, Abliva AB's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Abliva AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Abliva to invest in growth at high rates of return. When we think about Abliva AB's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives			INSIDER Age
	Kristina Luthman	Oncopeptides AB	N/A
	MSc MD	Oncopeptides AB	N/A
	Nina Valkama	Cantargia AB	N/A
	Adnan Deronic	Cantargia AB	N/A
	Leopold Bertea	Mendus AB	58
	MSc MSc	Oncopeptides AB	53
	Pr MD	Oncopeptides AB	N/A
	Jeroen MD	Mendus AB	52
	Linda Holmstrom	Oncopeptides AB	N/A
	MD MBA	Mendus AB	60
	Erik Manting	Mendus AB	52
	Jakob Lic	Oncopeptides AB	51
	Susanne Lagerlund	Cantargia AB	N/A
	Thoas MD	Cantargia AB	61
	Annika MBA	Oncopeptides AB	57
	Julie Silber	Alligator Bioscience AB	N/A
	Sren Bregenholt	Alligator Bioscience AB	52
	Johanna Christensen	Cantargia AB	N/A
	Dominique Tersago	Cantargia AB	61
	Peter Madsen	Cantargia AB	N/A
	Marcuss	Cantargia AB	N/A

Abliva AB , a pharmaceutical company, engages in the research and development of mitochondrial medicine. Abliva AB was incorporated in 2000 and is headquartered in Lund, Sweden. Abliva AB is traded on Stockholm Stock Exchange in Sweden. Abliva AB (ABLI) is traded on Stockholm Exchange in Sweden and employs 8 people.

Management Performance

	Return On Equity	-0.8
	Return On Asset	-0.41

Abliva AB Leadership Team

Elected by the shareholders, the Abliva AB's board of directors comprises two types of representatives: Abliva AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Abliva. The board's role is to monitor Abliva AB's management team and ensure that shareholders' interests are well served. Abliva AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Abliva AB's outside directors are responsible for providing unbiased perspectives on the board's policies.

	Lars Vedin, Consultant
	Magnus Hansson, Chief Devel
	Eskil Elmr, Chief Discovery
	Ellen Donnelly, Chief Officer
	Catharina Johansson, CFO CEO
	Daniel Schale, Director Communications

Abliva Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Abliva AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Equity	-0.8
	Return On Asset	-0.41
	Current Valuation	103.38 M
	Shares Outstanding	1.06 B
	Shares Owned By Insiders	7.79 %
	Shares Owned By Institutions	49.04 %
	Price To Book	0.97 X
	Price To Sales	2,681 X
	Revenue	151 K
	Gross Profit	(103.54 M)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Abliva Stock Analysis

When running Abliva AB's price analysis, check to measure Abliva AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abliva AB is operating at the current time. Most of Abliva AB's value examination focuses on studying past and present price action to predict the probability of Abliva AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abliva AB's price. Additionally, you may evaluate how the addition of Abliva AB to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC